Market Overview

Mallinckrodt Eyes Restructuring Ahead Of Cleveland Opioid Trial: 'Bankruptcy A Real Option'

Mallinckrodt Eyes Restructuring Ahead Of Cleveland Opioid Trial: 'Bankruptcy A Real Option'

Mallinckrodt PLC (NYSE: MNK) shares have been on an extended downtrend since the middle of 2015. From over $130 in early 2015, the stock is now barely above $1.

Much of the downside is attributable to allegations regarding opioid addiction and opioid overdose deaths that implicate not only Mallinckrodt, but a host of companies, including Purdue Pharma and Teva Pharmaceutical Industries Ltd (NYSE: TEVA).

Bankruptcy Option On The Table

Mallinckrodt shares were tumbling yet again Thursday, dropping about 45%, after Bloomberg reported that the company is exploring options that include a possible bankruptcy filing, ahead of a trial in Cleveland coming up next month.

The company has reportedly hired law firm Latham & Watkins and turnaround firm AlixPartners to assist in tackling the legal onslaught.

Endo International PLC (NASDAQ: ENDP) and Allergan plc (NYSE: AGN) have settled claims by agreeing to make payments ahead of the trial in Cleveland federal court.

Mallinckrodt is in talks with lawyers representing plaintiff cities and counties to wriggle out of the Cleveland trial, Bloomberg said, citing people familiar with the talks.

For Mallinckrodt, the problem at hand is exacerbated by its precarious cash position. The company has a debt pile of $5 billion, with only $550 million in cash on hand.

It has also depleted the last of its borrowing capacity, Bloomberg said, quoting analysts.

See also: Biotech Stock On The Radar: Ardelyx Gears Up For FDA Decision Day

BMO No Longer Recommends Equity 

With the situation turning from bad to worse, BMO Capital Markets analyst Gary Nachman downgraded Mallinckrodt from Outperform to Market Perform and lowered the price target from $19 to $3.

The analyst had previously stuck with his bullish view on the premise that the shares were undervalued and due to hopes the company can ultimately emerge from the opioid-related uncertainties and the significant pressure faced by its key Acthar franchise.

"However, with the rapidly mounting pressures related to the opioid litigation, we can no longer rule out the possibility of bankruptcy," the analyst said in a Wednesday downgrade note. 

"But it appears that is now a real option being considered and we can no longer recommend the equity."

Legal Woes Abound

Apart from the opioid entanglement, Mallinckrodt is facing other legal woes. It has locked horns with Praxair over a patent infringement lawsuit pertaining to the latter's nitric oxide drug product delivery system.

Further, the company has ongoing litigation with the U.S. government over the latter's decision to have the company change the base date average manufacturer price used to calculate Medicaid drug rebates for Acthar gel.

Mallinckrodt shares were down 39% at $1.58 at the time of publication Thursday. 

Related Link: The Daily Biotech Pulse: Cheery Results For Sage's Depression Drug, UniQure Offering, Axsome Aces Study Of Headache Drug

Latest Ratings for MNK

Apr 2020BarclaysMaintainsEqual-Weight
Apr 2020CFRAMaintainsHold
Feb 2020B of A SecuritiesMaintainsUnderperform

View More Analyst Ratings for MNK
View the Latest Analyst Ratings


Related Articles (MNK)

View Comments and Join the Discussion!

Posted-In: Analyst Color Biotech News Downgrades Health Care Price Target Legal Analyst Ratings Best of Benzinga

Latest Ratings

XPOJP MorganMaintains84.0
UPSJP MorganMaintains113.0
UNPJP MorganMaintains163.0
NSCJP MorganMaintains189.0
MCHPJP MorganMaintains100.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at